skip to main content

Enteropathic arthritis — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardSpondyloarthropathiesEnteropathic arthritisSCE Rheumatology

A patient with axial spondyloarthritis has active disease despite NSAIDs and also has recurrent anterior uveitis. Which advanced-therapy consideration is most relevant?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — A monoclonal TNF inhibitor

The best answer is “A monoclonal TNF inhibitor”. In axial spondyloarthritis, recurrent uveitis is an important extra-articular feature that can favour a monoclonal TNF inhibitor over alternatives with less consistent ocular benefit. Etanercept is not preferred for this purpose, chronic systemic glucocorticoids are not definitive axial therapy, and uveitis should inform rather than preclude biological treatment.

Reference: BSR axial spondyloarthritis biologic and targeted synthetic DMARD guideline: https://academic.oup.com/rheumatology/article/64/6/3242/8108015